The largest independent specialty pharmacy in the United States, Diplomat Pharmacy Inc. has announced that the FDA approved Jakafi for treatment of Polycythemia. Jakafi is a new drug recently launched by the Incyte Corporation and is used as treatment for patients suffering of polycythemia Vera and also from high or inter-mediate risk of myelofibrosis.
The FDA approved Jakafi for treatment of polycythemia vera, a chronic bone marrow disease, in people that do not have an adequate response to hydroxyurea. Hydroxyurea is a medication that is used often to reduce the platelets and red blood cells numbers in the blood.
Polycythemia Vera happens when too many red blood cells are made inside the bone marrow. This excess of blood cells may lead to bleeding issues, clots of blood inside veins near the surface of the skin and the swelling of the spleen. Patients suffering from polycythemia vera may also be at a higher risk of stroke and heart attack. It has been estimated that around 100,000 people in the United States are suffering from polycythemia vera, out of which around 25,000 cases are considered to be uncontrollable.
Even though Polycythemia Vera is a rare disease, the hematologists have diagnosed and treated the disease properly. Polycythemia Vera is a condition in which the blood cell number is increased and the blood stream thickens. Effects of this condition include thromboembolism and more frequent strokes for patients suffering from it. The surplus of red blood cells is isolated in the spleen which would eventually become larger. Polycythemia Vera is by nature clonal so specialists describe the disease as being malignant or pre-malignant. This condition may prove to be dangerous later on. The disease can be quickly detected by a routine check of the blood, and is evidenced by a higher level of hemoglobin.
The FDA approved Jakafi for treatment of polycythemia vera under the priority review program of the Federal Drug Administration and it is the first drug that has been approved for this condition. The Federal Drug Administration has previously approved in 2011 the drug Jakafi for treatment of people suffering of high or inter-mediate risk myleofibrosis, which is another disorder regarding bone marrow.